Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Endometrial stromal sarcomas.

J L Mansi1, S Ramachandra, E Wiltshaw

  • 1Department of Medical Oncology, Royal Marsden Hospital, London, England.

Gynecologic Oncology
|January 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

N-terminal pro B type natriuretic peptide, but not the new putative cardiac hormone relaxin, predicts prognosis in patients with chronic heart failure.

Heart (British Cardiac Society)·2003
Same author

Transcardiac and transpulmonary gradients in the putative new cardiovascular hormone relaxin.

Heart (British Cardiac Society)·2003
Same author

Calponin and h-caldesmon expression in synovial sarcoma; the use of calponin in diagnosis.

Histopathology·2003
Same author

Tumour thickness predicts cervical nodal metastases and survival in early oral tongue cancer.

Oral oncology·2003
Same author

Hb Q-India: an uncommon variant diagnosed in three Punjabi patients with diabetes is identified by a novel DNA analysis test.

Journal of clinical pathology·2003
Same author

Imaging features of aggressive angiomyxoma.

Clinical radiology·2003
Same journal

Toward precision prognosis: Predicting recurrence-free survival in high-grade serous ovarian cancer patients using multi-time point clinical and computed tomography radiomics data.

Gynecologic oncology·2026
Same journal

Adjunctive sodium-glucose cotransporter 2 (SGLT2) inhibitors with progestins and endometrial cancer risk in benign uterine diseases and hyperplasia.

Gynecologic oncology·2026
Same journal

Updated patient-reported outcomes and the effect of disease progression on health-related quality of life in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer.

Gynecologic oncology·2026
Same journal

PRO-PLATINUM: A randomized, double-blind, placebo controlled study to investigate the efficacy of a probiotic intervention on the gut and vaginal microbiome of ovarian cancer patients undergoing treatment with platinum chemotherapy.

Gynecologic oncology·2026
Same journal

A second chance for the second look: Feasibility of laparoscopic HIPEC at the conclusion of upfront treatment for epithelial ovarian cancer.

Gynecologic oncology·2026
Same journal

Prognostic impact of time to first recurrence in low-grade serous ovarian carcinoma: A multicentric retrospective study from the French TMRG network.

Gynecologic oncology·2026
See all related articles

Endometrial stromal sarcoma patients with low-grade tumors show good survival post-surgery without immediate therapy. High-grade tumors necessitate adjuvant radiotherapy and chemotherapy upon relapse.

Area of Science:

  • Gynecologic Oncology
  • Surgical Pathology
  • Oncologic Therapeutics

Background:

  • Endometrial stromal sarcoma (ESS) is a rare uterine malignancy.
  • Treatment strategies for ESS require further elucidation based on tumor grade.

Purpose of the Study:

  • To evaluate the impact of tumor grade on patient outcomes and treatment response in endometrial stromal sarcoma.
  • To determine optimal therapeutic strategies for low-grade versus high-grade ESS.

Main Methods:

  • Retrospective review of 15 patients with endometrial stromal sarcoma treated between 1973 and 1987.
  • Histological classification of tumors into low-grade and high-grade categories.
  • Analysis of survival data, relapse patterns, and treatment responses.

Related Experiment Videos

Main Results:

  • Low-grade ESS patients demonstrated prolonged relapse-free and overall survival, with minimal need for adjuvant therapy.
  • High-grade ESS patients experienced frequent local relapse, with three deaths within the study cohort.
  • Hormonal therapy showed efficacy in low-grade ESS, while chemotherapy was more suited for high-grade ESS.

Conclusions:

  • Adjuvant radiotherapy is recommended for high-grade ESS post-surgery.
  • Observation without immediate adjuvant therapy may be suitable for low-grade ESS patients.
  • Hormone therapy is the preferred first-line treatment for recurrent low-grade ESS, whereas chemotherapy is indicated for high-grade ESS recurrence.